| Literature DB >> 33648890 |
Tuo Yang1, Sabine Ottilie1, Eva S Istvan2, Karla P Godinez-Macias3, Amanda K Lukens4, Beatriz Baragaña5, Brice Campo6, Chris Walpole7, Jacquin C Niles8, Kelly Chibale9, Koen J Dechering10, Manuel Llinás11, Marcus C S Lee12, Nobutaka Kato13, Susan Wyllie5, Case W McNamara14, Francisco Javier Gamo15, Jeremy Burrows6, David A Fidock16, Daniel E Goldberg2, Ian H Gilbert5, Dyann F Wirth4, Elizabeth A Winzeler17.
Abstract
The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories. The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process by identifying new, essential, druggable targets. In addition, it seeks to produce early lead inhibitors that may be advanced into drug candidates suitable for preclinical development and subsequent clinical testing in humans. By sharing resources, including expertise, knowledge, materials, and reagents, the consortium strives to eliminate the structural barriers often encountered in the drug discovery process. Here we discuss the mission of the consortium and its scientific achievements, including the identification of new chemically and biologically validated targets, as well as future scientific directions.Entities:
Keywords: MalDA; Plasmodium falciparum; drug resistance; malaria; target-based drug discovery
Year: 2021 PMID： 33648890 DOI： 10.1016/j.pt.2021.01.009
Source DB: PubMed Journal: Trends Parasitol ISSN： 1471-4922